Seeking Alpha

Sarepta Therapeutics (SRPT) gets a 3% premarket lift from an initiation at Needham (Buy)....

Sarepta Therapeutics (SRPT) gets a 3% premarket lift from an initiation at Needham (Buy). Analyst Chad Messer is positive on eteplirsen and says he believes "the market reacted inappropriately to last week's regulatory update." The FDA requested "additional information" last Monday in order to evaluate an Accelerated Approval application, news the market did not like. (See also: Leerink Swann uncertain about SRPT)
From other sites
Comments (1)
  • pat walsh
    , contributor
    Comments (286) | Send Message
     
    I thought the request by the FDA was good news.We shall see.
    22 Apr 2013, 09:05 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs